A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash

Acneiform Eruptions Clinical Trial

Official title:
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash in Subjects With Neoplasm Receiving EGFRi or MEKi Therapy

Status Terminated

Clinical Trial Summary

Efficacy and Safety of imsidolimab in participants with epidermal growth factor receptor inhibitor (EGFRi)/mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor (MEKi)-associated acneiform Rash

Clinical Trial Description

This study is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of imsidolimab compared with placebo in cancer participants with EGFRi/MEKi-associated acneiform rash. This study will also characterize the pharmacokinetic (PK) profile of imsidolimab and explore the immune response to imsidolimab in participants with EGFRi/MEKi-associated acneiform rash. ;

Study Design

Related Conditions & MeSH terms

Acneiform Eruptions

Clinical Trial Details

NCT number	NCT04697069
Study type	Interventional
Source	AnaptysBio, Inc.
Contact
Status	Terminated
Phase	Phase 2
Start date	May 4, 2021
Completion date	December 13, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04864717` - Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI	Phase 4
Active, not recruiting	`NCT05120362` - A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin Rash	N/A
Recruiting	`NCT05919810` - The Effects of Oral Probiotics and Herbal Supplementation on the Gut Microbiome and Sebum Excretion Rate in Non-Cystic Acne	N/A